ArticleBiomaterials science2019
Engineering an immunomodulatory drug-eluting stent to treat laryngotracheal stenosis.
Article in Biomaterials science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- A survey of patients with laryngotracheal stenosis on future clinical trial design.Clinical trials (London, England) · 2022Trial
- Therapeutic Potential of Allicin in Multi-System Inflammatory Diseases.Current issues in molecular biology · 2026Review
- Balloon-expandable trilayer nitrided iron/Zn/poly-D,L-lactic acid metallic tracheal stent: structural characterization, mechanical performance, and short-term safety evaluation in rabbits.Journal of thoracic disease · 2026Article
- The benefit and effectiveness of biodegradable drug-coated stents in treating refractory pediatric laryngotracheal stenosis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Toll Like Receptors in the Larynx: Implications for Laryngeal Immunology.The Laryngoscope · 2025Article
- Preclinical Vocal Fold and Airway Injury Models: A Scoping Review.Laryngoscope investigative otolaryngology · 2025Review
- Anti-inflammatory coupled anti-angiogenic airway stent effectively suppresses tracheal in-stents restenosis.Journal of nanobiotechnology · 2025Article
- Advances in studies on tracheal stent design addressing the related complications.Materials today. Bio · 2024Review
- Oral Everolimus Following Dilation in Idiopathic Subglottic Stenosis: A Phase 1 Nonrandomized Clinical Trial.JAMA otolaryngology-- head & neck surgery · 2024Article
- An Ovine Model Yields Histology and Gene Expression Changes Consistent with Laryngotracheal Stenosis.The Laryngoscope · 2024Article
- Long-Term Survival and Regeneration Following Transplantation of 3D-Printed Biodegradable PCL Tracheal Grafts in Large-Scale Porcine Models.Bioengineering (Basel, Switzerland) · 2024Article
- Drug delivery systems for wound healing treatment of upper airway injury.Expert opinion on drug delivery · 2024Review
- Antimicrobial and Antiproliferative Coatings for Stents in Veterinary Medicine-State of the Art and Perspectives.Materials (Basel, Switzerland) · 2023Review
- Amelioration of Subglottic Stenosis by Antimicrobial Peptide Eluting Endotracheal Tubes.Cellular and molecular bioengineering · 2023Article
- Sirolimus-eluting airway stent reduces profibrotic Th17 cells and inhibits laryngotracheal stenosis.JCI insight · 2023Article
- A narrative review of progress in airway stents.Journal of thoracic disease · 2022Review
- Molecular Mechanisms and Physiological Changes behind Benign Tracheal and Subglottic Stenosis in Adults.International journal of molecular sciences · 2022Review
- Patterned Drug-Eluting Coatings for Tracheal Stents Based on PLA, PLGA, and PCL for the Granulation Formation Reduction: In Vivo Studies.Pharmaceutics · 2021Article
- Glutamine Inhibition Reduces Iatrogenic Laryngotracheal Stenosis.The Laryngoscope · 2021Article
- Post-intubation subglottic stenosis: aetiology at the cellular and molecular level.European respiratory review : an official journal of the European Respiratory Society · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectiveDevelop a drug-eluting stent construct with a reliable drug-release profile and adequate mechanically stability for a trial in a small animal model of laryngotracheal stenosis (LTS), a debilitating pathologic narrowing of the airway leading to significant shortness of breath.
methodsBiodegradable, biocompatible stents containing 1.0% rapamycin made of PLLA-PCL (70% Poly-l-Lactide and 30% Polycaprolactone blend) and 50 : 50 PDLGA (Poly(dl-lactide-co-glycolide)) were compared. Mechanical strength testing and drug elution rates using high performance liquid chromatography analysis (HPLC) was assessed. Next, efficacy of stent elution on LTS derived scar fibroblasts. Finally, stents were placed in situ in an LTS mouse model.
resultsThe PLLA-PCL stent construct exhibited greater mechanical strength compared to the PDLGA stent over a 4-week period (Young's Modulus (PLLA-PCL) = 13.82; Young's Modulus (PDLGA) = 4.015). Moreover, the PLLA-PCL stent showed a reliable rapamycin release profile for 6 weeks (30% elution for PLLA-PCL stents compared to <1% elution for PDLGA). Collagen 1 (p < 0.05) and fibroblast cell proliferation were decreased in vitro when treated with the rapamycin stent. In vivo, the rapamycin stent reduced lamina propria thickness (p < 0.05) and collagen 1(p < 0.05), collagen 3, TGF-B (p < 0.05) and a-SMA (p < 0.05).
conclusionsThe PLLA-PCL construct demonstrated superior mechanical strength and greater drug elution compared to PDLGA stents. We demonstrated the feasibility of testing this drug-eluting stent in vivo, showing that the rapamycin-eluting stent treats fibrosis. To our knowledge this is the first study to deploy a drug-eluting stent to treat tracheal pathology in an animal model. Optimization of a rapamycin-eluting PLLA-PCL stent for translational investigation will lead to improved treatment strategies of LTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.